Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

Benzinga · 1d ago
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $7 to $5.